Mounjaro, a innovative medication, is sparking considerable interest within the glycemic care community . This twin-mechanism injectable drug combines a GLP-1 receptor agonist with a glucose-dependent insulinotropic hormone , offering a apparently significant improvement in glycemic levels for individuals managing T2D . Early research results sugge